Related Experiment Videos
Reversible cortical atrophy and cognitive decline induced by valproic acid
R Straussberg1, S Kivity, R Weitz
1Department of Child Neurology, Schneider Children's Medical Center, Petah Tiqva, Israel.
Summary
This case study highlights a rare adverse reaction to sodium valproate in a young patient with familial progressive myoclonic epilepsy. Discontinuation of the drug led to significant cognitive improvement, suggesting a potential link.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Familial progressive myoclonic epilepsy (FPME) is a rare inherited neurological disorder.
- Sodium valproate is a commonly used antiepileptic drug.
Observation:
- An 18-year-old male with FPME experienced a severe decline in cognitive function after initiating sodium valproate therapy.
- The patient presented with stupor and moderate mental retardation, despite therapeutic serum valproate levels.
Findings:
- Discontinuation of sodium valproate resulted in a significant improvement in cognitive functions over four months.
- Initial MRI showed mild cortical atrophy, which resolved on follow-up imaging after valproate cessation.
Implications:
- This case suggests a potential neurotoxic effect of sodium valproate in certain individuals with epilepsy.
- Careful monitoring of cognitive function is crucial in patients treated with sodium valproate, especially those with pre-existing neurological conditions.